A drug designed to shut down fat production inside the liver could become a major new weapon against one of the world's fastest-growing liver diseases.
Researchers at University of California San Diego School of Medicine reported that an experimental treatment called ION224 produced significant improvements in people with metabolic dysfunction-associated steatohepatitis (MASH), an aggressive form of fatty liver disease strongly linked to obesity and type 2 diabetes. The condition can quietly progress for years before leading to cirrhosis, liver failure, or liver cancer.
The findings were published in The Lancet and drew attention because the drug attacks a biological pathway directly involved in liver fat buildup. Instead of simply helping patients lose weight or manage symptoms, ION224 targets the disease process itself.
How the Experimental Drug Works
ION224 blocks an enzyme known as DGAT2, which helps the liver produce and store fat. Scientists believe excess fat inside liver cells triggers inflammation, tissue damage, and scarring over time.
